Beacon eye gene therapy hits mark in late-stage study

Beacon's gene therapy for X-linked retinitis pigmentosa achieved its primary endpoint in a pivotal phase 3 trial, marking the first successful treatment for this rare eye disease.

This Wire brief sits within Fusion42's coverage of Biotech, Drug Discovery and Medtech, and 2 sources have reported it.